Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.
To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.
Disease | Cross reference | Weighted score | Related literature |
---|
We collected disease MeSH terms mapped to the references associated with tacrolimus
There are no associated biomedical information in the current reference collection.
Associated locations are in red color. Not associated locations are in black.
Location | Cross reference | Weighted score | Related literatures |
---|
Function | Cross reference | Weighted score | Related literatures |
---|
Lipid concept | Cross reference | Weighted score | Related literatures |
---|
Gene | Cross reference | Weighted score | Related literatures |
---|
There are no associated biomedical information in the current reference collection.
Authors | Title | Published | Journal | PubMed Link |
---|---|---|---|---|
Lee C et al. | FK-506 binding protein from Tolypocladium inflatum: resistance of FKBP/FK-506 complex against proteolysis. | 1992 | Biochem. Biophys. Res. Commun. | pmid:1371677 |
Lepre CA et al. | Solution structure of FK506 bound to FKBP-12. | 1992 | FEBS Lett. | pmid:1375171 |
Abu-Elmagd K et al. | Management of intestinal transplantation in humans. | 1992 | Transplant. Proc. | pmid:1376523 |
Hanke JH et al. | FK506 and rapamycin selectively enhance degradation of IL-2 and GM-CSF mRNA. | 1992 | Lymphokine Cytokine Res. | pmid:1281674 |
Dumont FJ et al. | The immunosuppressive and toxic effects of FK-506 are mechanistically related: pharmacology of a novel antagonist of FK-506 and rapamycin. | 1992 | J. Exp. Med. | pmid:1380976 |
Hultsch T et al. | The effect of the immunophilin ligands rapamycin and FK506 on proliferation of mast cells and other hematopoietic cell lines. | 1992 | Mol. Biol. Cell | pmid:1384815 |
Mizuno K et al. | Modulation of multidrug resistance by immunosuppressive agents: cyclosporin analogues, FK506 and mizoribine. | 1992 Jan-Feb | Anticancer Res. | pmid:1373592 |
Arai S et al. | The impact of FK506 on graft coronary disease of rat cardiac allograft--a comparison with cyclosporine. | 1992 Jul-Aug | J. Heart Lung Transplant. | pmid:1379829 |
Fagiuoli S et al. | FK 506: a new immunosuppressive agent for organ transplantation. Pharmacology, mechanism of action and clinical applications. | 1992 Jul-Aug | Ital J Gastroenterol | pmid:1381245 |
Tong J et al. | Effect of FK-506 and cyclosporin A on in vitro CFU-GM growth in severe aplastic anemia patients. | 1992 Jul-Aug | Haematologica | pmid:1385279 |
Nazer H et al. | FK 506 associated disorders in liver transplantation. | 1992 May-Jun | J. Gastroenterol. Hepatol. | pmid:1377038 |
Bowman H and Lennard TW | Immunosuppressive drugs. | 1992 Nov 4-17 | Br J Hosp Med | pmid:1282440 |
Sattler M et al. | Cytochrome P-450 3A enzymes are responsible for biotransformation of FK506 and rapamycin in man and rat. | 1992 Sep-Oct | Drug Metab. Dispos. | pmid:1385058 |
Doi R et al. | Biochemical characterization of the effects of FK506 on signal transduction in exocytotic function of rat pancreatic acini. | 1993 | J. Pharmacol. Exp. Ther. | pmid:7679738 |
Gunji Y et al. | Pathologic characteristics of vasculitis in renal transplant recipient dogs receiving immunosuppressive agents, FK 506, rapamycin, or RS-61443. | 1993 | Transplant. Proc. | pmid:7679841 |
Gregory CR et al. | Effects of treatment with cyclosporine, FK 506, rapamycin, mycophenolic acid, or deoxyspergualin on vascular muscle proliferation in vitro and in vivo. | 1993 | Transplant. Proc. | pmid:7679842 |
Zeevi A et al. | Comparative in vitro studies on the immunosuppressive effects of purine and pyrimidine synthesis inhibitors. | 1993 | Transplant. Proc. | pmid:7679843 |
Reese JC et al. | The effect of FK506 on canine bile flow. | 1993 | Transplantation | pmid:7504342 |
Woodle ES et al. | FK506--reversal of humorally mediated cardiac allograft rejection in the presence of preformed anti-class I antibody. | 1993 | Transplantation | pmid:7504346 |
Jindal RM et al. | Effect of deoxyspergualin on the endocrine function of the rat pancreas. | 1993 | Transplantation | pmid:7504347 |
Kodama M et al. | FK506 therapy of experimental autoimmune myocarditis after onset of the disease. | 1993 | Am. Heart J. | pmid:7504393 |
Nishinaka Y et al. | Protective effect of FK506 on ischemia/reperfusion-induced myocardial damage in canine heart. | 1993 | J. Cardiovasc. Pharmacol. | pmid:7681507 |
Luan S et al. | Immunosuppressants implicate protein phosphatase regulation of K+ channels in guard cells. | 1993 | Proc. Natl. Acad. Sci. U.S.A. | pmid:7681590 |
Doi R et al. | Structural and functional changes of exocrine pancreas induced by FK506 in rats. | 1993 | Gastroenterology | pmid:7681795 |
Rotonda J et al. | Improved calcineurin inhibition by yeast FKBP12-drug complexes. Crystallographic and functional analysis. | 1993 | J. Biol. Chem. | pmid:7681823 |
Simek SL et al. | Sequence and localization of a novel FK506-binding protein to mouse chromosome 11. | 1993 | Genomics | pmid:7507077 |
Quesniaux VF | Immunosuppressants: tools to investigate the physiological role of cytokines. | 1993 | Bioessays | pmid:7507316 |
Hill CC et al. | Penile prosthesis surgery in the immunosuppressed patient. | 1993 | Transplantation | pmid:7692633 |
Roberts JP et al. | Reversal of chronic rejection after treatment failure with FK506 and RS61443. | 1993 | Transplantation | pmid:7692634 |
Storb R et al. | FK-506 and methotrexate prevent graft-versus-host disease in dogs given 9.2 Gy total body irradiation and marrow grafts from unrelated dog leukocyte antigen-nonidentical donors. | 1993 | Transplantation | pmid:7692635 |
McDiarmid SV et al. | A comparison of renal function in cyclosporine- and FK-506-treated patients after primary orthotopic liver transplantation. | 1993 | Transplantation | pmid:7692636 |
Ochiai T et al. | Combination of immunosuppressive drugs for organ transplantation. | 1993 | Ann. N. Y. Acad. Sci. | pmid:7509136 |
Denesyuk AI et al. | Structural similarity of the binding sites of cyclophilin A-cyclosporin A and FKBP-FK506 systems. | 1993 | Biochem. Biophys. Res. Commun. | pmid:7683466 |
Wiederrecht G et al. | The mechanism of action of FK-506 and cyclosporin A. | 1993 | Ann. N. Y. Acad. Sci. | pmid:7509138 |
Waschulewski IH et al. | Effects of the immunosuppressants cyclosporin A and FK 506 on exocytosis in the rat exocrine pancreas in vitro. | 1993 | Br. J. Pharmacol. | pmid:7683567 |
Morikawa K et al. | Immunosuppressive activity of fosfomycin on human T-lymphocyte function in vitro. | 1993 | Antimicrob. Agents Chemother. | pmid:7509146 |
Ohtake M et al. | Enhanced liver regeneration in rats treated with 15-deoxyspergualin alone and in combination with FK 506. | 1993 | Gastroenterol. Jpn. | pmid:7683616 |
Murphy MP and Morris RE | Brequinar sodium effectively and potently suppresses allograft rejection in a heterotopic mouse heart transplant model. | 1993 | Transplant. Proc. | pmid:7685955 |
Li W and Handschumacher RE | Specific interaction of the cyclophilin-cyclosporin complex with the B subunit of calcineurin. | 1993 | J. Biol. Chem. | pmid:7686148 |
Wong PY et al. | Recurrence of primary biliary cirrhosis after liver transplantation following FK506-based immunosuppression. | 1993 | J. Hepatol. | pmid:7686192 |
Sakr MF et al. | FK 506 pre-treatment is associated with reduced levels of tumor necrosis factor and interleukin 6 following hepatic ischemia/reperfusion. | 1993 | J. Hepatol. | pmid:7686193 |
Jacobs JC et al. | Pyoderma gangrenosum in infancy. | 1993 | J. Am. Acad. Dermatol. | pmid:7688775 |
Garrity GM et al. | Genetic relationships among actinomycetes that produce the immunosuppressant macrolides FK506, FK520/FK523 and rapamycin. | 1993 | J. Ind. Microbiol. | pmid:7688970 |
Hoof T et al. | Reversal of multidrug resistance in Chinese hamster ovary cells by the immunosuppressive agent rapamycin. | 1993 | Eur. J. Pharmacol. | pmid:7689059 |
Lieberman R | FK506, artificial intelligence and pharmacoeconomics. | 1993 | J Clin Pharmacol | pmid:7690045 |
McMichael J et al. | An intelligent and cost-effective computer dosing system for individualizing FK506 therapy in transplantation and autoimmune disorders. | 1993 | J Clin Pharmacol | pmid:7690046 |
Jain AB et al. | Pharmacokinetics of FK506 in liver transplant recipients after continuous intravenous infusion. | 1993 | J Clin Pharmacol | pmid:7690047 |
Langrehr JM et al. | Clinical course, morphology, and treatment of chronically rejecting small bowel allografts. | 1993 | Transplantation | pmid:7679526 |
Uemoto S et al. | Experience with FK506 in living-related liver transplantation. | 1993 | Transplantation | pmid:7679528 |
Talento A et al. | A single administration of LFA-1 antibody confers prolonged allograft survival. | 1993 | Transplantation | pmid:7679531 |